Table 2.

Sample characteristics.

Sample types	Vaccine time point	Used sample amount	Input DNA (ng)	T cells by nucleotide sequence	Clonotypes by nucleotide sequence	T cells by amino acid sequence	Clonotypes by amino acid sequence
PBMC	Pre	8 × 106 cells	2,852	252,926	195,744	252,926	187,972
	Post-2	8 × 106 cells	2,861	253,155	199,650	253,155	191,481
	Post-4	8 × 106 cells	3,428	313,245	149,604	313,245	144,519
Stimulated CD3+ T cells	Pre	6.8 × 106 cells	1,204	166,173	88,391	166,173	85,767
	Post-2	6.5 × 106 cells	1,202	158,747	78,715	158,747	76,644
	Post-4	2 × 106 cells	1,202	99,701	29,150	99,701	28,643
LBC	Pre	1,200 μL	318	814	699	814	694
	Post-4	800 μL	930	10,731	6748	10,731	6,693
FFPE	Pre	Five 5μm scrolls	392	403	372	403	359
	Post-4	Five 5μm scrolls	934	382	344	382	331

T cell clone abundances were counted using complementarity determining region 3 (CDR3) nucleotide or amino acid sequences. PBMC, peripheral blood mononuclear cells; CD3+ T cells, CD3+ T cells stimulated with HPV16 E6 and E7 antigens expressed by recombinant vaccinia viruses and in GST-fusion proteins; LBC, liquid-based cytology; FFPE, formalin-fixed paraffin-embedded.